Lymphoma
Conditions
Keywords
stage I mantle cell lymphoma, contiguous stage II mantle cell lymphoma, noncontiguous stage II mantle cell lymphoma, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, recurrent mantle cell lymphoma
Brief summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which treatment regimen is more effective for lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of rituximab in treating patients who have follicular or mantle cell lymphoma.
Detailed description
OBJECTIVES: * Assess the clinical efficacy of consolidation treatment with rituximab in terms of response rate in patients with follicular (closed to accrual 9/18/00) or mantle cell lymphoma. * Compare the event free survival of patients after induction with or without consolidation. * Compare the tolerability of these two treatment regimens by these patients. OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to participating center, histology (follicular (closed to accrual 9/18/00) vs mantle cell), status of disease (de novo vs relapsed vs resistant), response after induction (stable disease vs partial or complete response), and treatment status (treated vs untreated). All patients receive induction therapy consisting of rituximab IV over 3-5 hours once a week during weeks 1-4. Patients are then randomized to one of two treatment arms. * Arm I: Patients are observed. * Arm II: Patients receive rituximab IV over 3-5 hours once a week during weeks 12, 20, 28, and 36. Patients are followed weekly for the first month; every 8 weeks for the next 8 months; then at 12, 18, and 24 months; and then annually for the next 3 years. PROJECTED ACCRUAL: A total of 240 patients (120 per arm) will be accrued for this study within 3-4 years.
Interventions
BIOLOGICALrituximab
Sponsors
Swiss Cancer Institute
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically proven CD20 positive follicular (closed to accrual 9/18/00) or mantle cell lymphoma * Untreated de novo disease OR * Chemotherapy resistant disease OR * Relapsing disease * Bidimensionally measurable disease * No symptomatic CNS disease PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 3 months Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 2 times upper limit of normal (ULN) * No hepatitis B or C Renal: * Creatinine no greater than 2 times ULN Cardiovascular: * Ejection fraction at least 50% Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No active opportunistic infections * HIV negative * No prior malignancy within 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior antibody based therapy Chemotherapy: * At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas) and recovered * No concurrent chemotherapy Endocrine therapy: * At least 4 weeks since prior corticosteroids, unless chronic dose no greater than 20 mg/day for nonlymphoma related condition * No other concurrent corticosteroids Radiotherapy: * Not specified Surgery: * Not specified
Countries
Switzerland
Outcome results
None listed